eMarketer’s July article featuring M3 MI data explores the relationship between major retailers, drug manufacturers, pharmacy benefit managers (PBMs), health insurers, and consumers within the context of the Trump administration’s recent efforts to help lower drug costs by bypassing the middlemen. It is currently unclear how retailers would fit in with these government’s plans and unlikely we’d see PBM’s removed from the equation, especially considering MARS 2025 data reports that most consumers’ medications are included in their insurance plans (or purchased with supplemental plans/benefits, like FSAs/HSAs). Will we see any major shake ups in the pharmaceutical industry, and will consumers see any real savings?